ClinicalTrials.gg
CompletedNCT00924560Updated Oct 22, 2014Results posted

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

A Phase 2 interventional study of 91-day Levonorgestrel Oral Contraceptive and 28-day Levonorgestrel Oral Contraceptive in Bone Mineral Density, sponsored by Duramed Research. Completed at 46 sites in United States. Open to female participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-22.

Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,361
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
Female
01

Study summary

This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.

Read the detailed description

Participants will be randomized to either a 91-day OC or a 28-day OC. Participants not seeking hormonal contraception who meet eligibility criteria will serve as a control group. Duration of the study for each study participant will be approximately 13 months.

02

Conditions studied

  • Bone Mineral Density

Keywords

  • Adolescents
  • Bone Mineral Density
  • Oral Contraceptive
03

In context

Lead sponsor

Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.

First submitted after Duramed Research became part of Teva Pharmaceutical Industries, Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy postmenarchal adolescent female 12-18 years old, non-pregnant, nonlactating
  • Regular spontaneous menstrual cycles
  • (BMI): 18 kg/m² to \<30 kg/m², weight \< 200 lbs
  • Others as dictated by the Food and Drug Administration (FDA)-approved protocol

Exclusion criteria

Exclusion Criteria:

  • Any to the use of oral
  • History of previous adverse event while taking hormonal contraceptives
  • Use of any medication which could significantly interfere with study assessments
  • Others as dictated by FDA-approved protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,361 participants (actual)

Study arms

  • Experimental
    91-day Levonorgestrel Oral Contraceptive

    Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).

    Drug: 91-day Levonorgestrel Oral Contraceptive

  • Active comparator
    28-day Levonorgestrel Oral Contraceptive

    Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).

    Drug: 28-day Levonorgestrel Oral Contraceptive

  • No intervention
    Untreated Control

    Participants received no oral contraceptives during the study.

Interventions

  • Drug91-day Levonorgestrel Oral Contraceptive

    Drug pages: Levonorgestrel · Ethinyl Estradiol

    Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet. Take 1 tablet daily

    Also known as: levonorgestrel/ethinyl estradiol, DR-105, Seasonique®

  • Drug28-day Levonorgestrel Oral Contraceptive

    Drug pages: Levonorgestrel · Ethinyl Estradiol

    Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily

    Also known as: levonorgestrel/ethinyl estradiol, Lessina®

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)

    Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline \* 100%.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Change From Baseline in Lumbar Spine Bone Mineral Density

    Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  2. Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)

    Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  3. Change From Baseline in Proximal Femur Bone Mineral Density

    Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  4. Change From Baseline in Proximal Femur Bone Mineral Content (BMC)

    Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  5. Change From Baseline in Total Body Bone Mineral Density

    Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  6. Change From Baseline in Total Body Bone Mineral Content (BMC)

    Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

    Time frame: Baseline, Month 6 and Month 12

  7. Change From Baseline in Bone-specific Alkaline Phosphatase

    Time frame: Baseline, Month 6 and Month 12

  8. Change From Baseline in Serum Deoxypyridinoline

    Time frame: Baseline, Month 6 and Month 12

  9. Change From Baseline in Serum Osteocalcin

    Time frame: Baseline, Month 6 and Month 12

  10. Change From Baseline in Serum Procollagen 1 N-terminal Propeptide

    Time frame: Baseline, Month 6 and Month 12

  11. Change From Baseline in Serum Type I Collagen N-telopeptide

    Time frame: Baseline, Month 6 and Month 12

  12. Number of Participants With Adverse Events (AEs)

    An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below. A severe AE is defined as incapacitating, with inability to perform usual activities. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions: * fatal or life-threatening; * required or prolonged inpatient hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly or birth defect; * important medical event.

    Time frame: 12 months

07

Results

Posted Oct 9, 2014

Participant flow

Healthy, postmenarcheal, adolescent females who were either willing to be randomly assigned to 1 of 2 open-label oral contraceptive (OC) treatment regimens or who were not seeking current treatment with hormonal contraceptives and agreed not to use hormonal contraception throughout the 12-month duration of the study (control group).

Participant flow — Overall Study
Milestone91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Started458448455
Received treatment4224110
Completed247240372
Not completed21120883
Withdrew: Did not meet protocol requirements421
Withdrew: Non compliance with the protocol20154
Withdrew: Physician decision234
Withdrew: Withdrawal by subject504418
Withdrew: Adverse event39330
Withdrew: Pregnancy571
Withdrew: Lost to follow-up789445
Withdrew: Miscellaneous reasons131010

Outcome measures

PrimaryPercent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline \* 100%.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)
percent change91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)2.26 ± 0.1681.45 ± 0.1712.50 ± 0.139
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.23 · 95% CI -0.67 to 0.20Difference = OC group minus the untreated control
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -1.05 · 95% CI -1.49 to -0.61Difference = OC group minus the untreated control
SecondaryChange From Baseline in Lumbar Spine Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g/cm^2
Change From Baseline in Lumbar Spine Bone Mineral Density
g/cm^291-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 60.02 ± 0.0010.01 ± 0.0010.01 ± 0.001
Change from Baseline to Month 120.02 ± 0.0020.01 ± 0.0020.03 ± 0.001
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.00 · 95% CI -0.00 to 0.01
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.01 · 95% CI -0.01 to -0.00
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to 0.00
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.01 · 95% CI -0.02 to -0.01
SecondaryChange From Baseline in Lumbar Spine Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g
Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)
g91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 61.29 ± 0.0950.69 ± 0.0971.12 ± 0.079
Change from Baseline to Month 121.86 ± 0.1201.20 ± 0.1221.94 ± 0.099
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.17 · 95% CI -0.08 to 0.42
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.43 · 95% CI -0.68 to -0.18
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.07 · 95% CI -0.39 to 0.24
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.74 · 95% CI -1.05 to -0.42
SecondaryChange From Baseline in Proximal Femur Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g/cm^2
Change From Baseline in Proximal Femur Bone Mineral Density
g/cm^291-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=238, 227, 358)0.01 ± 0.0010.00 ± 0.0010.01 ± 0.001
Change from Baseline to Month 12 (n=238, 224, 359)0.02 ± 0.0020.01 ± 0.0020.01 ± 0.001
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.00 · 95% CI 0.00 to 0.01
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to 0.00
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.01 · 95% CI 0.00 to 0.01
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 0.95% CI -0.01 to 0.00
SecondaryChange From Baseline in Proximal Femur Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g
Change From Baseline in Proximal Femur Bone Mineral Content (BMC)
g91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=238, 227, 358)0.26 ± 0.0590.09 ± 0.0610.13 ± 0.049
Change from Baseline to Month 12 (n=238, 224, 359)0.59 ± 0.0660.28 ± 0.0680.43 ± 0.055
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.13 · 95% CI -0.03 to 0.28
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.04 · 95% CI -0.20 to 0.11
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: 0.16 · 95% CI -0.01 to 0.34
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.14 · 95% CI -0.32 to 0.03
SecondaryChange From Baseline in Total Body Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g/cm^2
Change From Baseline in Total Body Bone Mineral Density
g/cm^291-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=130, 126, 149)0.01 ± 0.0010.01 ± 0.0010.01 ± 0.001
Change from Baseline to Month 12 (n=130, 126, 150)0.01 ± 0.0020.01 ± 0.0020.02 ± 0.001
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to 0.00
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to 0.00
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to -0.00
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -0.00 · 95% CI -0.01 to -0.00
SecondaryChange From Baseline in Total Body Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Least squares mean · g
Change From Baseline in Total Body Bone Mineral Content (BMC)
g91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=130, 126, 149)40.77 ± 6.57138.70 ± 6.63846.26 ± 6.231
Change from Baseline to Month 12 (n=130, 126, 150)72.86 ± 8.32563.78 ± 8.40984.95 ± 7.871
Statistical analysis
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -5.48 · 95% CI -23.57 to 12.61
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -7.55 · 95% CI -25.65 to 10.55
  • 91-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -12.09 · 95% CI -34.99 to 10.81
  • 28-day Levonorgestrel OC vs Untreated Control · Ls mean difference: -21.17 · 95% CI -44.08 to 1.74
SecondaryChange From Baseline in Bone-specific Alkaline Phosphatase
Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · µg/L
Change From Baseline in Bone-specific Alkaline Phosphatase
µg/L91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=236, 224, 353)-6.8 ± 8.31-5.9 ± 7.84-6.2 ± 10.42
Change from Baseline to Month 12 (n=235, 225, 347)-6.9 ± 8.64-6.6 ± 8.82-10.3 ± 12.49
SecondaryChange From Baseline in Serum Deoxypyridinoline
Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · nmol/L
Change From Baseline in Serum Deoxypyridinoline
nmol/L91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=234, 224, 349)-0.1 ± 2.43-0.1 ± 1.950.1 ± 2.33
Change from Baseline to Month 12 (n=233, 226, 348)-0.1 ± 2.210.1 ± 2.05-0.1 ± 2.28
SecondaryChange From Baseline in Serum Osteocalcin
Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · nmol/L
Change From Baseline in Serum Osteocalcin
nmol/L91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=236, 224, 354)-4.8 ± 7.00-3.9 ± 6.74-5.1 ± 11.94
Change from Baseline to Month 12 (n=235, 225, 348)-4.5 ± 6.69-3.7 ± 7.19-7.1 ± 11.74
SecondaryChange From Baseline in Serum Procollagen 1 N-terminal Propeptide
Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · µg/L
Change From Baseline in Serum Procollagen 1 N-terminal Propeptide
µg/L91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=237, 225, 355)-49.9 ± 58.55-38.7 ± 51.14-57.8 ± 92.58
Change from Baseline to Month 12 (n=235, 226, 349)-50.4 ± 60.20-39.8 ± 55.73-86.0 ± 118.69
SecondaryChange From Baseline in Serum Type I Collagen N-telopeptide
Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · nM bone collagen equivalents (BCE)
Change From Baseline in Serum Type I Collagen N-telopeptide
nM bone collagen equivalents (BCE)91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Change from Baseline to Month 6 (n=235, 224, 356)-4.8 ± 9.69-3.9 ± 10.68-0.7 ± 13.60
Change from Baseline to Month 12 (n=236, 225, 350)-4.5 ± 10.22-4.3 ± 10.71-3.1 ± 12.64
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below. A severe AE is defined as incapacitating, with inability to perform usual activities. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions: * fatal or life-threatening; * required or prolonged inpatient hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly or birth defect; * important medical event.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participants91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
Any adverse event252258274
Severe adverse event142010
Treat-related adverse event100957
Deaths000
Other serious adverse events9120
Withdrawn from study due to adverse events34331

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
91-day Levonorgestrel OC—9/421 (2.1%)156/421 (37.1%)
28-day Levonorgestrel OC—12/412 (2.9%)160/412 (38.8%)
Untreated Control—0/437 (0%)196/437 (44.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
Event91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
AppendicitisInfections and infestations2/4211/4120/437
Wolff-Parkinson-White syndromeCardiac disorders0/4211/4120/437
SerositisGeneral disorders0/4211/4120/437
Clostridial infectionInfections and infestations0/4211/4120/437
Post concussion syndromeInjury, poisoning and procedural complications0/4211/4120/437
Knee deformityMusculoskeletal and connective tissue disorders0/4211/4120/437
Abortion incompletePregnancy, puerperium and perinatal conditions0/4211/4120/437
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/4211/4120/437
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/4211/4120/437
Affective disorderPsychiatric disorders0/4211/4120/437
Most frequent other events
Most frequent other events
Event91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated Control
HeadacheNervous system disorders65/42169/41288/437
NasopharyngitisInfections and infestations35/42152/41253/437
Upper respiratory tract infectionInfections and infestations30/42127/41253/437
DysmenorrhoeaReproductive system and breast disorders20/42126/41237/437
MetrorrhagiaReproductive system and breast disorders29/42114/4120/437
Oropharyngeal painRespiratory, thoracic and mediastinal disorders14/42110/41230/437
NauseaGastrointestinal disorders18/42125/41214/437
ArthralgiaMusculoskeletal and connective tissue disorders9/42114/41222/437

Baseline characteristics

Age, Continuous
Age, Continuous(years)91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated ControlTotal
Mean16.0 ± 1.6115.9 ± 1.7114.8 ± 1.7215.6 ± 1.77
Sex: Female, Male
Sex: Female, Male(Participants)91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated ControlTotal
Female4584484551361
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)91-day Levonorgestrel OC28-day Levonorgestrel OCUntreated ControlTotal
African-American878772246
Asian391224
Caucasian251265255771
Hispanic10279111292
Other158528
08

Study locations

46 sites
  • Teva Investigational Site 007
    Phoenix, Arizona, United States
  • Teva Investigational Site 018
    Phoenix, Arizona, United States
  • Teva Investigational Site 005
    Tucson, Arizona, United States
  • Teva Investigational Site 047
    North Little Rock, Arkansas, United States
  • Teva Investigational Site 027
    La Mesa, California, United States
  • Teva Investigational Site 040
    Los Angeles, California, United States
  • Teva Investigational Site 037
    Mountain View, California, United States
  • Teva Investigational Site 013
    San Diego, California, United States
  • Teva Investigational Site 017
    San Diego, California, United States
  • Teva Investigational Site 025
    Torrance, California, United States
  • Teva Investigational Site 022
    Washington, District of Columbia, United States
  • Teva Investigational Site 004
    Boynton Beach, Florida, United States
  • Teva Investigational Site 008
    Clearwater, Florida, United States
  • Teva Investigational Site 026
    DeLand, Florida, United States
  • Teva Investigational Site 001
    Miami, Florida, United States
  • Teva Investigational Site 003
    Miami, Florida, United States
  • Teva Investigational Site 028
    Tampa, Florida, United States
  • Teva Investigational Site 041
    West Palm Beach, Florida, United States
  • Teva Investigational Site 034
    Champaign, Illinois, United States
  • Teva Investigational Site 023
    Louisville, Kentucky, United States
  • Teva Investigational Site 021
    Baton Rouge, Louisiana, United States
  • Teva Investigational Site 030
    St. Louis, Missouri, United States
  • Teva Investigational Site 009
    Lincoln, Nebraska, United States
  • Teva Investigational Site 010
    Lawrenceville, New Jersey, United States
  • Teva Investigational Site 038
    Port Jefferson, New York, United States
  • Teva Investigational Site 048
    Rochester, New York, United States
  • Teva Investigational Site 002
    Durham, North Carolina, United States
  • Teva Investigational Site 043
    Kernersville, North Carolina, United States
  • Teva Investigational Site 044
    New Bern, North Carolina, United States
  • Teva Investigational Site 020
    Raleigh, North Carolina, United States
  • Teva Investigational Site 006
    Winston-Salem, North Carolina, United States
  • Teva Investigational Site 033
    Cleveland, Ohio, United States
  • Teva Investigational Site 012
    Medford, Oregon, United States
  • Teva Investigational Site 035
    Pittsburgh, Pennsylvania, United States
  • Teva Investigational Site 039
    Pottstown, Pennsylvania, United States
  • Teva Investigational Site 036
    Providence, Rhode Island, United States
  • Teva Investigational Site 032
    Charleston, South Carolina, United States
  • Teva Investigational Site 024
    Columbia, South Carolina, United States
  • Teva Investigational Site 046
    Dallas,, Texas, United States
  • Teva Investigational Site 031
    Houston, Texas, United States
  • Teva Investigational Site 045
    Houston, Texas, United States
  • Teva Investigational Site 011
    Waco, Texas, United States
  • Teva Investigational Site 015
    Salt Lake City, Utah, United States
  • Teva Investigational Site 019
    Norfolk, Virginia, United States
  • Teva Investigational Site 014
    Seattle, Washington, United States
  • Teva Investigational Site 016
    Spokane, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 2 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2009
First posted
Jun 19, 2009
Start
Jun 2009
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results delay requested
Apr 10, 2013
Results first posted
Oct 9, 2014
Last update
Oct 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00924560
Lead sponsor
Duramed Research
Responsible party
Sponsor
First posted
Jun 19, 2009
Start date
Jun 2009
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Oct 9, 2014
Last update
Oct 22, 2014

Study contacts

Jen Henrick
study chair · Teva GBP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion